Cheng Xin / Getty Images Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped. The biotech firm also posted a decline in sales outside the U.S. because of ...

Proceeds from Vertex’s (ASX:VTX) $11m capital raising will support the start of underground mining this year at its Hill End gold project.

Vertex Rail Technologies opened in Wilmington in 2014 with promises of over 1,300 jobs and a $60 million investment. Despite initial optimism and orders, the company faced setbacks including ...

For Vertex Pharmaceuticals, the first quarter of 2025 brought good news and bad news. On the bright side, early momentum for newly launched cystic fibrosis (CF) med Alyftrek and pain treatment ...

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the company's innovation. The company recently has expanded into another area ...

Vertex Pharmaceuticals reported disappointing Q1 revenue and earnings. The company also revealed it is temporarily pausing part of a phase 1/2 study of experimental cystic fibrosis drug VX-522 ...

Eli Lilly has reached a deal to acquire SiteOne Therapeutics that would give it control of a non-opioid pain drug that would compete with a recently approved therapy from Vertex Pharma.

Vertex Pharmaceuticals recently reported a decline in net income and EPS for Q1 2025, despite a rise in revenue, which was accompanied by a large $379 million impairment charge related to its ...

Vertex Pharmaceuticals Inc. (VRTX), a prominent player in the biotechnology industry with a market capitalization of $128.7 billion, reported its first quarter 2025 earnings, revealing a miss on ...

Higher costs and issues with Russia led Vertex Pharmaceuticals to miss profit and sales estimates. Constellation Energy beat revenue forecasts and reiterated its full-year earnings guidance on ...

Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its drugs for cystic fibrosis, and little or no contributions from a gene ...